---
title: "Radiopharm Theranostics Reports Business Update"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294505146.md"
description: "Results from a Phase 2b clinical trial of the imaging agent RAD 101 have been positive, with 93% of evaluated patients who received RAD 101 meeting the primary endpoint. This indicates a promising outcome for the study involving this agent."
datetime: "2026-07-31T11:02:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294505146.md)
  - [en](https://longbridge.com/en/news/294505146.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294505146.md)
generator: "portal-rs"
---

# Radiopharm Theranostics Reports Business Update

Results from a Phase 2b clinical trial of the imaging agent RAD 101 have been positive, with 93% of evaluated patients who received RAD 101 meeting the primary endpoint. This indicates a promising outcome for the study involving this agent.

### Related Stocks

- [RADX.US](https://longbridge.com/en/quote/RADX.US.md)

## Related News & Research

- [Radiopharm schedules FDA end-of-Phase 2 meeting to align Phase 3 trial design for RAD101 brain metastases imaging agent](https://longbridge.com/en/news/296102289.md)
- [Lantheus Holdings Discloses Investment at Radiopharm Theranostics with 20.9% Stake](https://longbridge.com/en/news/298075040.md)
- [ZAWYA: Oman oil price tops $101 per barrel amid renewed US-Iran fighting](https://longbridge.com/en/news/297889094.md)
- [Radiopharm teams up with Siemens Healthineers to manufacture, distribute RAD101 doses for US Phase 3 trial](https://longbridge.com/en/news/296098148.md)
- [Why Is Penny Stock Datavault AI (DVLT) Down Today?](https://longbridge.com/en/news/298059853.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**